Investment
Features
FeesSafety
Academy
More
Pluang+

Thermal Energy to release Q4 and full-year 2026 results on Sept 22 with a live webcast and Q&A.

Company Fundamentals
17 Sep 2026
Newsfile Corp
View Source
Neutral
Thermal Energy to release Q4 and full-year 2026 results on Sept 22 with a live webcast and Q&A.

Thermal Energy International Inc. will announce its fiscal 2026 fourth quarter and full-year financial results before market open on September 22, 2026. The company will host a live webcast and conference call at 8:30 a.m. ET the same day, including a Q&A session for analysts and investors. Financial statements and management's discussion will be available on SEDAR+ and the company's website following the release. This update is important for investors tracking the company’s performance in energy efficiency and emissions reduction solutions globally.

Thermal Energy International's upcoming fiscal 2026 results provide context for energy sector activity. For readers following the energy sector, here is Pluang's market snapshot as of Sep 17, 2026 18:11 WIB: Among 30 priced US energy stocks, 21 rose and 8 fell. Devon Energy Corp (DVN) traded at USD 48.64 with a 1-day change of +0.41% and a typical hold time of 134 days, while Cenovus Energy Inc (CVE) was at USD 32.39, down 0.40%, with a much shorter hold time of 45 days and a high buy order activity of 95%. Kinder Morgan Inc (KMI) stood at USD 30.85, up 0.39%, with a hold time of 148 days and 69% buy orders on Pluang.

More News

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...

Company Fundamentals
Neutral
17 minutes ago
Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...

Analyst Insights
Bullish
1 hour ago
Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...

Analyst Insights
Bullish
1 hour ago
Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...

Analyst Insights
Bullish
2 hours ago
$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

An investment of $10,000 in Marvell stock a decade ago has grown to approximately $206,000 today. Achieving the same growth again would require an annual earnings increase of 35%. This highlights Marvell's strong past performance and the challenge of...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App